New research is reshaping how experts view popular weight loss medications, suggesting that their benefits may extend far beyond the number on the scale.
Drugs like Wegovy and Zepbound—both part of a class known as GLP-1 receptor agonists—are widely used to help people shed excess weight. However, studies now indicate that even those who don’t experience significant weight loss may still gain meaningful health improvements.
Benefits Beyond the Scale
According to recent findings, approximately 10% to 15% of individuals taking GLP-1 medications do not lose a substantial amount of weight. Despite this, clinical trials suggest these drugs can still deliver major health benefits.
Researchers have found that these medications may lower the risk of heart attacks and strokes, while also improving outcomes for people living with heart failure. These effects appear to occur independently of weight loss, challenging long-held assumptions about how the drugs work.
Promising Impact on Liver Health
Emerging evidence also points to benefits for liver conditions. Wegovy has recently received approval from the U.S. Food and Drug Administration for treating a serious liver disease known as metabolic dysfunction-associated steatohepatitis.
This development highlights the drug’s potential role in addressing metabolic disorders beyond obesity.
Experts Urge a Broader Perspective
Medical experts say these findings could change how the effectiveness of such treatments is measured.
Dr. Daniel Drucker noted that while weight loss has traditionally been seen as the primary driver of improvement, new data suggests there may be more at play.
“We have seen hints… that weight loss isn’t the whole story,” he explained, pointing to underlying metabolic changes triggered by the drugs.
Similarly, Dr. Jody Dushay emphasized that insurance policies may need to evolve. Currently, many insurers require patients to lose at least 5% of their body weight within a few months to continue coverage.
With growing evidence of broader health benefits, experts argue that this standard may no longer reflect the full value of these medications.
A Shift in Treatment Goals
The new findings could mark a turning point in how obesity and metabolic health are approached. Rather than focusing solely on weight loss, healthcare providers may begin to prioritize overall health improvements, including cardiovascular and liver function.
As research continues, GLP-1 medications like Wegovy and Zepbound could play an even larger role in treating a wide range of serious conditions—regardless of how much weight a patient loses.
